Seeking Alpha·3d ago
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call TranscriptXenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals (XENE) reports a development-stage cost structure in which R&D expense of $95.6M in 2026Q3 consumed roughly 80% of the cost base, while revenue appeared in only one of the last ten quarters at $7.5M in 2025Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | -$1.11+1.8% vs -$1.13 | — vs $500,000 |
Q3 2026 Aug 6, 2026 | -$1.11+2.6% vs -$1.14 | — vs $2M |
Q2 2026 May 7, 2026 | -$1.17+0.0% vs -$1.17 | — vs $1M |
Q1 2026 Feb 26, 2026 | -$1.31-9.2% vs -$1.20 | — vs $178,571 |
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and advancing two pain treatments into midstage testing.
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and planned Q1 2027 initiation of Phase 3b/4 X-FIRST study evaluating azetukalner as first add-on ASM Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026 Positive Phase 1 data for novel, non-opioid pain programs XEN1701 (Na V 1.7) and XEN1120 (K V 7) presented at IASP World Congress on Pain support initiating Phase 2 proof-of-concept studies in acute pain; studies expected to initiate in H1 2027 Cash, cash equivalents and marketable securities of $1.2 billion with cash runway into 2029 Conference call at 4:30 pm EST today VANCOUVER, BC and BOSTON, MA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2026 and provided a business update. “We've made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities.
VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the fourth quarter of 2026.
Benchmark XENE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xenon Pharmaceuticals Inc. (XENE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.00 | $3.96B | -9.54 | — | -4612.13% | -39.8% | — | |
| $324.76 | $9.05B | -26.36 | -100% | — | -29.41% | — | |
| $18.14 | $3.11B | 8.79 | 11.87% | 30.13% | 28.03% | — | |
| $63.36 | $5.26B | -49.91 | 114.51% | -9.17% | — | — | |
| $6.87 | $443.26M | -47.28 | -0.3% | -3.45% | -2% | — | |
| $2.55 | $475.93M | -5.45 | 1181.27% | -2178.9% | -23.64% | — |
Xenon Pharmaceuticals Inc. (XENE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xenon Pharmaceuticals Inc. (XENE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 9, 2026·SEC
Aug 6, 2026·SEC
May 7, 2026·SEC
Get notified when XENE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xenon Pharmaceuticals Inc. (XENE) stock FAQ — growth, dividends, profitability & financials explained
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue in fiscal year 2025. That is 48% less than the $14.3M of fiscal year 2012.
Xenon Pharmaceuticals Inc. (XENE) revenue fell by 100.0% over the trailing twelve months, compared with the twelve months before.
No. Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $428.7M over the trailing twelve months.
Xenon Pharmaceuticals Inc. (XENE) had a return on equity (ROE) of -39.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $357.1M over the trailing twelve months.
